Caribou Biosciences Q2 EPS $(0.48) Beats $(0.49) Estimate, Sales $3.75M Beat $3.07M Estimate
Portfolio Pulse from Benzinga Newsdesk
Caribou Biosciences (NASDAQ:CRBU) reported Q2 losses of $(0.48) per share, beating the analyst consensus estimate of $(0.49) by 2.04 percent. This is a 9.09 percent decrease over losses from the same period last year. The company also reported quarterly sales of $3.75 million, beating the analyst consensus estimate of $3.07 million by 22.31 percent, but a 10.42 percent decrease over sales from the same period last year.
August 08, 2023 | 8:51 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Caribou Biosciences reported better than expected Q2 earnings and sales, but both earnings and sales decreased compared to the same period last year.
While Caribou Biosciences beat analyst estimates for Q2 earnings and sales, the company reported a decrease in both earnings and sales compared to the same period last year. This mixed result could lead to neutral short-term price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100